Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Mersana Therapeutics Second Quarter 2025 Financial Results and Business Update Conference Call and Webcast.
Mersana Therapeutics Inc. (MRSN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 226,954.08 | $1,679,457 | -26% | 0.01% |
| 2. | AQR Capital Management Cliff Asness | 205,187.4 | $1,518,386 | -1% | 0% |
| 3. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 152,587.36 | $1,129,146 | 0.07% | |
| 4. | SilverArc Capital Devesh Gandhi | 125,136.84 | $926,013 | +2% | 0.17% |
| 5. | Renaissance Technologies Jim Simons | 114,007.76 | $843,657 | +240% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.20 | 14,760 | $47,181.82 | 8,663,673 | 2022-06-02 | Filing | |
| $3.28 | 80,759 | $264,776.46 | 8,648,913 | 2022-05-31 | Filing | |
| $3.19 | 75,000 | $238,942.50 | 8,568,154 | 2022-05-26 | Filing | |
| $3.18 | 90,155 | $286,242.13 | 8,493,154 | 2022-05-25 | Filing | |
| $3.29 | 100,000 | $328,990.00 | 8,402,999 | 2022-05-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.58 | 3,554 | $2,061.32 | 57,519 | 2025-01-16 | Filing | |
| $0.58 | 8,637 | $5,009.46 | 168,041 | 2025-01-16 | Filing | |
| $0.58 | 8,048 | $4,667.84 | 257,673 | 2025-01-16 | Filing | |
| $0.58 | 4,514 | $2,618.12 | 122,875 | 2025-01-16 | Filing | |
| $0.58 | 8,470 | $4,912.60 | 121,393 | 2025-01-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 482,689.84 | $3,571,905 | 0.68% | |
| 2. | 346,546.92 | $2,564,447 | 0.32% | |
| 3. | 307,135.64 | $2,272,803 | 0% | |
| 4. | 150,536.76 | $1,113,973 | 0% | |
| 5. | 57,350.4 | $424,393 | 0% |
News See All
Mersana Therapeutics Presents Positive Phase 1 Data for Cancer Drug Emi-Le at ASCO 2025
Mersana Therapeutics Inc. (NASDAQ:MRSN) is one of the best penny stocks under $1 to buy now.
12 Best Penny Stocks Under $1 to Buy Now
On July 18, Greg Tuorto of Goldman Sachs joined CNBC's 'Closing Bell' to state that the small-cap market is starting to show signs of life.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Mersana Therapeutics First Quarter 2025 Conference Call. Currently all participants are in a listen-only mode.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2024 Conference Call. Currently all participants are in a listen-only mode.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Mersana Therapeutics Third Quarter 2024 Conference Call. Currently all participants are in listen-only mode.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2024 Earnings Call Transcript August 13, 2024Mersana Therapeutics, Inc. misses on earnings expectations.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the Mersana Therapeutics First Quarter 2024 Conference Call and Webcast. Currently, all participants are in listen-only mode.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Mersana Therapeutics Fourth Quarter 2023 Conference Call and Webcast. Currently, all participants are in listen-only mode.
5 Best Rising Penny Stocks To Buy
Monopar Therapeutics (NASDAQ:MNPR) recently jumped after the company reported positive preclinical data for its MNPR-101 program.